Mayne Well Positioned to Weather the Storm; Maintaining FVE and Very High Uncertainty
We maintain our AUD 1.25 fair value estimate for no-moat Mayne Pharma given the recent update by management on the US generic industry trading...
154 Views
Financial Forensics - The Short-Seller's Indispensable Tool-Kit
Financial forensics remains an indispensable part of the short-seller's tool-kit. In this report, Evidente updates and expands its analysis of...
499 Views
Australian Growth Stocks: The Big Short (Still)
Four months ago, Evidente published a post suggesting that Australian growth stocks were over-priced The Big Short: Australian Growth Stocks and...
602 Views
Generic Drug Antitrust Inquiry: A Primer
Recent news stories reporting looming criminal antitrust charges against certain generic drug companies (and possibly executives) are wighing on...
393 Views
Re-Visiting the Big Short: Australian Growth Stocks
Last month, Evidente documented that the valuation dispersion between value and growth stocks was without precedent; the median book multiple of...
346 Views